# Aytu Biopharma, Inc: overview AYTU · Nasdaq · CIK 1385818 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30 Pages: [Overview](/companies/aytu.md) · [Financials](/companies/aytu/financials.md) · [Filings](/companies/aytu/filings.md) · [Insiders](/companies/aytu/insiders.md) Latest reported revenue: [$16.1m](/filings/0001437749-26-030908.md) for Q4 FY2026, three months to 2026-06-30, from the 10-K filed Sep 22, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001437749-26-030908). ## Last eight quarters | Line item | Unit | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [16.6](/filings/0001437749-25-034825.md) | [16.2](/filings/0001437749-26-002804.md) | [18.5](/filings/0001437749-26-016721.md) | [15.1 d](/filings/0001437749-26-030908.md) | [13.9](/filings/0001437749-25-034825.md) | [15.2](/filings/0001437749-26-002804.md) | [12.4](/filings/0001437749-26-016721.md) | [16.1 d](/filings/0001437749-26-030908.md) | | Gross margin | % | [72.3%](/filings/0001437749-25-034825.md) | [66.5%](/filings/0001437749-26-002804.md) | [69.4%](/filings/0001437749-26-016721.md) | [67.8% d](/filings/0001437749-26-030908.md) | [66.1%](/filings/0001437749-25-034825.md) | [63.5%](/filings/0001437749-26-002804.md) | [61.2%](/filings/0001437749-26-016721.md) | [64.6% d](/filings/0001437749-26-030908.md) | | Operating margin | % | [(5.6%)](/filings/0001437749-25-034825.md) | [(10.4%)](/filings/0001437749-26-002804.md) | [13.1%](/filings/0001437749-26-016721.md) | [(50.4%) d](/filings/0001437749-26-030908.md) | [(10.8%)](/filings/0001437749-25-034825.md) | [(13.0%)](/filings/0001437749-26-002804.md) | [(32.7%)](/filings/0001437749-26-016721.md) | [(4.8%) d](/filings/0001437749-26-030908.md) | | Net margin | % | [8.9%](/filings/0001437749-26-016721.md) | [4.9%](/filings/0001437749-26-016721.md) | [21.6%](/filings/0001437749-26-016721.md) | [(130.9%) d](/filings/0001437749-26-030908.md) | [14.1%](/filings/0001437749-26-016721.md) | [(69.8%)](/filings/0001437749-26-016721.md) | [(45.3%)](/filings/0001437749-26-016721.md) | [(0.1%) d](/filings/0001437749-26-030908.md) | | Diluted EPS | $ per share | [(0.15)](/filings/0001437749-25-034825.md) | [(0.26)](/filings/0001437749-26-002804.md) | [0.21](/filings/0001437749-26-016721.md) | not reported | [(0.08)](/filings/0001437749-25-034825.md) | [(1.05)](/filings/0001437749-26-002804.md) | [(0.53)](/filings/0001437749-26-016721.md) | not reported | | Free cash flow | $m | [(1.3)](/filings/0001437749-25-034825.md) | [2.9 d](/filings/0001437749-26-002804.md) | [(6.5) d](/filings/0001437749-26-016721.md) | [2.8 d](/filings/0001437749-26-030908.md) | [(0.6)](/filings/0001437749-25-034825.md) | [3.7 d](/filings/0001437749-26-002804.md) | [(4.2) d](/filings/0001437749-26-016721.md) | [4.4 d](/filings/0001437749-26-030908.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. ## Last five fiscal years | Line item | Unit | FY2022 (2022-06-30) | FY2023 (2023-06-30) | FY2024 (2024-06-30) | FY2025 (2025-06-30) | FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [96.7](/filings/0001558370-23-016393.md) | [107](/filings/0001437749-24-030062.md) | [65.2](/filings/0001437749-25-029723.md) | [66.4](/filings/0001437749-26-030908.md) | [57.6](/filings/0001437749-26-030908.md) | | Gross margin | % | [54.1%](/filings/0001558370-23-016393.md) | [62.0%](/filings/0001437749-24-030062.md) | [75.3%](/filings/0001437749-25-029723.md) | [69.0%](/filings/0001437749-26-030908.md) | [64.0%](/filings/0001437749-26-030908.md) | | Operating margin | % | [(113.7%)](/filings/0001558370-23-016393.md) | [(15.9%)](/filings/0001437749-24-030062.md) | [(2.4%)](/filings/0001437749-25-029723.md) | [(11.8%)](/filings/0001437749-26-030908.md) | [(14.4%)](/filings/0001437749-26-030908.md) | | Net margin | % | [(112.5%)](/filings/0001558370-23-016393.md) | [(15.9%)](/filings/0001437749-24-030062.md) | [(24.3%)](/filings/0001437749-25-029723.md) | [(20.4%)](/filings/0001437749-26-030908.md) | [(24.8%)](/filings/0001437749-26-030908.md) | | Diluted EPS | $ per share | [(74.01)](/filings/0001558370-23-016393.md) | [(5.11)](/filings/0001558370-23-016393.md) | not reported | not reported | not reported | | Free cash flow | $m | [(28.8)](/filings/0001558370-23-016393.md) | not reported | [(1.7)](/filings/0001437749-25-029723.md) | [(2.2)](/filings/0001437749-26-030908.md) | [3.3](/filings/0001437749-26-030908.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/aytu/insiders.md) | Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing | | --- | --- | --- | --- | ---: | ---: | ---: | --- | | 2020-04-15 | [Cerecor Inc.](/insiders/1534120.md) | 10% owner | Sale (S) | 92,777 | $1.5531 | $144.1k | [Form 4](/filings/0001578563-20-000020.md) | ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $2.3m | 1,086,812 | | Unchanged | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $2.3m | 1,086,812 | | Unchanged | | [Stonepine Capital Management, LLC](/funds/1440771.md) | 2026-06-30 | $2.0m | 912,921 | | Added +120,632 | | [AWM Investment Company, Inc.](/funds/1535264.md) | 2026-06-30 | $1.3m | 619,574 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $561.5k | 261,146 | | Unchanged | | [CROWN ADVISORS MANAGEMENT, INC.](/funds/1733248.md) | 2026-06-30 | $430.0k | 200,000 | | Added +55,000 | | [DIADEMA PARTNERS LP](/funds/2026172.md) | 2026-06-30 | $319.4k | 148,546 | | Reduced −204,531 | | [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $226.5k | 105,326 | | Reduced −16,647 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $225.4k | 104,823 | | Added +11,100 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $201.4k | 93,647 | | Added +1,011 | ## Recent filings [All 886 filings](/companies/aytu/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-22 | 16:30 ET | [DEF 14A](/filings/0001437749-26-033276.md) | Proxy statement, period 2026-12-10 | 0001437749-26-033276 | | 2026-09-22 | 16:14 ET | [10-K](/filings/0001437749-26-030908.md) | Annual report, period 2026-06-30 | 0001437749-26-030908 | | 2026-09-22 | 16:05 ET | [8-K](/filings/0001437749-26-030900.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-030900 | | 2026-06-25 | 16:31 ET | [8-K](/filings/0001437749-26-021707.md) | 1.02 Termination of a material agreement | 0001437749-26-021707 | | 2026-05-13 | 16:08 ET | [10-Q](/filings/0001437749-26-016721.md) | Quarterly report, period 2026-03-31 | 0001437749-26-016721 | | 2026-05-13 | 16:05 ET | [8-K](/filings/0001437749-26-016717.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-016717 | | 2026-04-02 | 16:08 ET | [8-K](/filings/0001437749-26-011116.md) | 1.01 Entry into a material agreement; 2.02 Results of operations; 3.02 Unregistered sale of equity; 3.03 Change to security holders’ rights; 9.01 Financial statements and exhibits | 0001437749-26-011116 | | 2026-02-03 | 16:08 ET | [10-Q](/filings/0001437749-26-002804.md) | Quarterly report, period 2025-12-31 | 0001437749-26-002804 | | 2026-02-03 | 16:05 ET | [8-K](/filings/0001437749-26-002799.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-002799 | | 2026-01-20 | 16:05 ET | [8-K](/filings/0001437749-26-001543.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-001543 | ## Latest annual report [Form 10-K for the fiscal year ended Jun 30, 2026](/filings/0001437749-26-030908.md), filed Sep 22, 2026. ## Forecast league Q1 FY2027, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/137556f8-d394-4295-82eb-64b04c695a70) ## About the filer - CIK: 1385818 - Tickers: AYTU - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 16:32 ET. No prices; not investment advice.